7-Bromo-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one

Catalog No. :
ACBQCI892
CAS No. :
3951-89-1
Molecular Formula :
C10H10BrNO
Molecular Weight :
240.10

IUPAC Name:7-bromo-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one

7-Bromo-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg96%$50.00Login to see priceIn stockIn stock
1g96%$148.00Login to see priceIn stockIn stock
5g96%$572.00Login to see priceIn stockInquiry
25g96%$2219.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7-Bromo-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one
IUPAC Name7-bromo-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one
MDL No.MFCD02168781
Molecular FormulaC10H10BrNO
Molecular Weight240.10
SMILESO=C1C2=CC(Br)=CC=C2NCCC1
InChI KeyXIFKOJPBXZKSAZ-UHFFFAOYSA-N
Synonym7-BROMO-1,2,3,4-TETRAHYDRO-BENZO[B]AZEPIN-5-ONE;7-Bromo-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one;7-bromo-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one;Tolvaptan impurity;7-BROMO-1,2,3,4-TETRAHYDRO-1-BENZAZEPIN-5-ONE;5H-1-Benzazepin-5-one, 7-bromo-1,2,3,4-tetrahydro-;7-Bromo-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one;Tovaptan impurity 17
CAS No.3951-89-1
PubChem CID22329108

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364

Synthetic Route by SureRoute

1. ACBQCI892 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBQCI892 route product structure diagram
    ACBQCI8923951-89-1 In Stock
Inquiry

2. ACBQCI892 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBQCI892 route product structure diagram
    ACBQCI8923951-89-1 In Stock
Inquiry

Comments (0)